Inhalable Dry Powders of Antimicrobial Agents in Respiratory Diseases
Hasham Shafi, David Encinas-Basurto, Y Peter Di, Heidi M Mansour · 2026
Read Inhalable Dry Powders of Antimicrobial Agents in Respiratory Diseases by Hasham Shafi, David Encinas-Basurto, Y Peter Di, Heidi M Mansour (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13582049.txt.
Description
Hasham Shafi and co-authors review in 2026 dry powder inhalers that deliver germ fighting drugs straight into the lungs for respiratory disease. Breathing drugs in can reach high levels where the infection sits while sparing the rest of the body. The review traces these inhalers from early mist therapies to today's engineered powders, across drugs that fight bacteria, viruses, and fungi.
It covers disease targets, drug choices, particle and formula design, device types, patents, trials, and approval milestones. Stress falls on formulas backed by animal results, human trials, or approval, in diseases such as tuberculosis and chronic lung infection. Dose, landing spot, and shelf stability remain the main bars to wider use.
Catalog record
| CREATOR | Hasham Shafi, David Encinas-Basurto, Y Peter Di, Heidi M Mansour |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |